Biochemical curative surgery for gastrinoma in multiple endocrine neoplasia type-1 patients

Department of Surgery, Kansa Electric Power Company Hospital, Osaka, Japan.
World Journal of Gastroenterology (Impact Factor: 2.37). 03/2011; 17(10):1343-53. DOI: 10.3748/wjg.v17.i10.1343
Source: PubMed


To search for the optimal surgery for gastrinoma and duodenopancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1.
Sixteen patients with genetically confirmed multiple endocrine neoplasia type 1 (MEN 1) and Zollinger-Ellison syndrome (ZES) underwent resection of both gastrinomas and duodenopancreatic neuroendocrine tumors (NETs) between 1991 and 2009. For localization of gastrinoma, selective arterial secretagogue injection test (SASI test) with secretin or calcium solution was performed as well as somatostatin receptor scintigraphy (SRS) and other imaging methods such as computed tomography (CT) or magnetic resonance imaging (MRI). The modus of surgery for gastrinoma has been changed over time, searching for the optimal surgery: pancreaticoduodenectomy (PD) was first performed guided by localization with the SAST test, then local resection of duodenal gastrinomas with dissection of regional lymph nodes (LR), and recently pancreas-preserving total duodenectomy (PPTD) has been performed for multiple duodenal gastrinomas.
Among various types of preoperative localizing methods for gastrinoma, the SASI test was the most useful method. Imaging methods such as SRS or CT made it essentially impossible to differentiate functioning gastrinoma among various kinds of NETs. However, recent imaging methods including SRS or CT were useful for detecting both distant metastases and ectopic NETs; therefore they are indispensable for staging of NETs. Biochemical cure of gastrinoma was achieved in 14 of 16 patients (87.5%); that is, 100% in 3 patients who underwent PD, 100% in 6 patients who underwent LR (although in 2 patients (33.3%) second LR was performed for recurrence of duodenal gastrinoma), and 71.4% in 7 patients who underwent PPTD. Pancreatic NETs more than 1 cm in diameter were resected either by distal pancreatectomy or enucleations, and no hepatic metastases have developed postoperatively. Pathological study of the resected specimens revealed co-existence of pancreatic gastrinoma with duodenal gastrinoma in 2 of 16 patients (13%), and G cell hyperplasia and/or microgastrinoma in the duodenal Brunner's gland was revealed in all of 7 duodenal specimens after PPTD.
Aggressive resection surgery based on accurate localization with the SASI test was useful for biochemical cure of gastrinoma in patients with MEN 1.

Download full-text


Available from: Izumi Komoto, Nov 28, 2014
30 Reads
  • Source
    • "A new option may be pancreas-preserving total duodenectomy that has been recently reported by Imamura and co-workers [57,58,59] in patients with multiple gastrinomas as part of MEN-1 syndrome. This challenging new technique awaits further investigations before it can be used as an alternative to pylorus-preserving pancreatico-duodenectomy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple endocrine neoplasia type 1 (MEN-1) is a rare autosomal-dominant disease. It is associated with a broad range of endocrine tumours, most frequently arising in the parathyroid glands, the pituitary and the pancreas. Most neuroendocrine tumours will be diagnosed in the pancreas as non-functioning neuroendocrine tumours or insulinomas. Forty-two percent of the patients will develop a gastrin-secreting neuroendocrine tumour, a gastrinoma. Gastrinomas in MEN-1 tend to be small, multiple and preferentially located in the duodenum. This paper will focus on the specific characteristics of gastrinomas in the setting of MEN-1 compared to sporadic gastrinomas. The developments in understanding the tumorigenesis of these tumours and the consequences for diagnosis and therapy will be discussed.
    Cancers 12/2012; 4(1):39-54. DOI:10.3390/cancers4010039
  • Source
    • "Bartsch et al.36 recommended pylorus-preserving partial duodenectomy, in order to prevent duodenal recurrence and to maintain postoperative quality of life. Imamura et al.29,37 recommended pancreaticoduodenectomy or pancreas-preserving total duodenectomy after fully identifying the location of tumor with SASI test, in order to improve the prognosis for complete cure and to prevent hepatic metastasis, provided that the tumor is located at the pancreatic head or duodenum; a high biochemical cure (87.5%) was obtained for gastrinoma.37 In this way, surgical treatment for MEN1-associated gastrinoma remains controversial. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.
    Gut and liver 07/2012; 6(3):287-94. DOI:10.5009/gnl.2012.6.3.287 · 1.81 Impact Factor
  • Source
    • "In our experience such recurrences have been treated with re-resection of the pancreatic neck or new enucleations rather than total pancreatectomy, but this may ultimately be required (55). Pancreas-preserving duodenectomy has been reported as an elegant technique to remove multiple duodenal gastrinomas entirely, but it is a difficult procedure suggested to benefit selected patients with multifocal duodenal gastrinomas, with the problem of leaving behind the possible common concomitant non-functioning pancreatic tumors (56)–(58). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatico-duodenal tumors are the second most common endocrinopathy in multiple endocrine neoplasia syndrome type 1, and have a pronounced effect on life expectancy as the principal cause of disease-related death. Previous discussions about surgical management have focused mainly on syndromes of hormone excess and, in particular, the management of multiple endocrine neoplasia syndrome type 1-related Zollinger-Ellison syndrome. Since hormonal syndromes tend to occur late and indicate the presence of metastases, screening with biochemical markers and endoscopic ultrasound is recommended for early detection of pancreatico-duodenal tumors, and with early surgery before metastases have developed. Surgery is recommended in patients with or without hormonal syndromes in the absence of disseminated liver metastases. The suggested operation includes distal 80% subtotal pancreatic resection together with enucleation of tumors in the head of the pancreas, and in cases with Zollinger-Ellison syndrome, excision of duodenal gastrinomas together with clearance of regional lymph node metastases. This strategy, with early and aggressive surgery before metastases have developed, is believed to reduce the risks for tumor recurrence and malignant progression.
    Clinics (São Paulo, Brazil) 04/2012; 67 Suppl 1(Suppl 1):173-8. DOI:10.6061/clinics/2012(Sup01)29 · 1.19 Impact Factor
Show more